{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:07:02Z","timestamp":1776722822612,"version":"3.51.2"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>To investigate the clinical features of immune checkpoint inhibitor (ICI)-associated myasthenia gravis (MG) with concurrent myocarditis with the aim of enhancing our understanding. We retrospectively analyzed the clinical data of a patient diagnosed with ICI-associated MG and myocarditis, and reviewed the relevant literature. A 67-year-old man was admitted with a 4-day history of right-sided ptosis and blurred vision. His medical history included resection of adenocarcinoma in the right upper lung lobe over 18 years ago and a diagnosis of new lung cancer in the right lower lobe four months prior to presentation. In May 2025, lung cancer recurrence was identified but the patient declined any treatment at that time. In September 2025, following radiotherapy and a single dose of serplulimab (a programmed cell death protein 1 inhibitor, PD-1), the patient developed clinical symptoms including ptosis, a positive fatigue test, and a positive neostigmine test, suggestive of myasthenia gravis. Biochemical tests, electrocardiogram (ECG), and echocardiography indicated myocarditis. The clinical diagnosis was ICI-associated myocarditis. Management involved the discontinuation of immunotherapy, administration of glucocorticoids, and symptomatic supportive treatment, which led to clinical improvement. A literature review summarized 45 cases, indicating that this overlapping immune-related adverse event is rare and has a poor prognosis. Multiple adverse reactions to ICIs can occur simultaneously. Prompt recognition of symptoms and initiation of targeted and effective treatments are crucial for optimizing clinical outcomes.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1764567","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:50:56Z","timestamp":1773903056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report and literature review: immune checkpoint inhibitor-associated myasthenia gravis and myocarditis"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhiyue","family":"Shang","sequence":"first","affiliation":[{"name":"Department of Neurology, Cardiovascular Hospital Affiliated to Shanxi Medical University; Shanxi Key Laboratory of Heart Failure Precision Medicine","place":["Taiyuan, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cardiovascular Hospital Affiliated to Shanxi Medical University; Shanxi Key Laboratory of Heart Failure Precision Medicine","place":["Taiyuan, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Cardiovascular Hospital Affiliated to Shanxi Medical University; Shanxi Key Laboratory of Heart Failure Precision Medicine","place":["Taiyuan, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weirong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Cardiovascular Hospital Affiliated to Shanxi Medical University; Shanxi Key Laboratory of Heart Failure Precision Medicine","place":["Taiyuan, Shanxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.3390\/ijms23073529","article-title":"Immune checkpoint receptors signaling in T cells","volume":"23","author":"Baldanzi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2019.05.008","article-title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial","volume":"116","author":"Reck","year":"2019","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","article-title":"Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"23","author":"Lee","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1410928","DOI":"10.3389\/fimmu.2024.1410928","article-title":"The role of the gut microbiota in tumor, immunity, and immunotherapy","volume":"15","author":"Xie","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"100683","DOI":"10.1016\/j.modpat.2024.100683","article-title":"Frequency and consequences of immune checkpoint inhibitor-associated inflammatory changes in different organs: an autopsy study over 13 -years","volume":"38","author":"Maccio","year":"2025","journal-title":"Mod Pathol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: eSMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an international car-dio-oncology society (IC-OS) consensus statement","volume":"43","author":"Joerg","year":"2022","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"ITC17","DOI":"10.7326\/AITC202402200","article-title":"Immune-related adverse events of immune checkpoint inhibitors","volume":"177","author":"Ramos-Casals","year":"2024","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10637-023-01347-6","article-title":"Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis","volume":"41","author":"Wang","year":"2023","journal-title":"Invest New Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/cei\/uxac108","article-title":"Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis","volume":"211","author":"Zhao","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia Gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/acn3.51761","article-title":"Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis","volume":"10","author":"Masi","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00520-023-07987-x","article-title":"Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series","volume":"31","author":"Weaver","year":"2023","journal-title":"Support Care Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00432-019-02927-x","article-title":"Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases","volume":"145","author":"Atallah-Yunes","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"B33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.gore.2018.05.014","article-title":"Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report","volume":"25","author":"Mahmood","year":"2018","journal-title":"Gynecol Oncol Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e210252","DOI":"10.1148\/ryct.210252","article-title":"Cardiac MRI assessment of nonischemic myocardial inflammation: state of the art review and update on myocarditis associated with COVID-19 vaccination","volume":"3","author":"Sanchez Tijmes","year":"2021","journal-title":"Radiol Cardiothorac Imaging"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1038\/s41467-023-41066-3","article-title":"Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects","volume":"14","author":"Cortellino","year":"2023","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/ehjacc\/zuae021","article-title":"Rate of cardiovascular events up to 8 years after uncomplicated myocarditis: a nationwide cohort study","volume":"13","author":"Schelldorfer","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.31083\/j.rcm2310335","article-title":"New diagnostic approach to arrhythmogenic cardiomyopathy: the Padua criteria","volume":"23","author":"Graziano","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12968-015-0217-y","article-title":"Mapping tissue inhomogeneity in acute myocarditis: a novel analytical approach to quantitative myocardial edema imaging by T2-mapping","volume":"17","author":"Bae\u00dfler","year":"2015","journal-title":"J Cardiovasc Magn Reson"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC scientific document group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3969\/j.issn.1000-8179.2020.20.148","article-title":"Chinese expert consensus on the surveillance and management of immune checkpoint inhibitor-related myocarditis (2020 version)","volume":"47","year":"2020","journal-title":"Chin J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3760\/cma.j.cn112152-20220213-00098","article-title":"Chinese expert consensus on diagnosis and treatment of neurologic immune-related adverse events associated with immune checkpoint inhibitors (2022 edition)","volume":"44","year":"2022","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.7539\/j.issn.1672-2981.2023.08.047","article-title":"Immune checkpoint inhibitor-associated myositis, myocarditis and myasthenia gravis overlap syndrome based on the US FDA adverse event reporting system","volume":"21","author":"Wu","year":"2023","journal-title":"Central South Pharmacy"},{"key":"B45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.21037\/jtd.2016.02.07","article-title":"Postoperative survival for patients with thymoma complicating myasthenia gravis-preliminary retrospective results of the ChART database","volume":"8","author":"Wang","year":"2016","journal-title":"J Thorac Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00000478-200101000-00012","article-title":"Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors","volume":"25","author":"Okumura","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B49","volume-title":"Chinese Society of Clinical Oncology (CSCO) Guideline for Cardio-Oncology 2023","year":"2023"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"156","DOI":"10.18999\/nagjms.87.1.156","article-title":"A case of severe immune-related adverse events, myocarditis with myositis, and myasthenia gravis overlap syndrome following adjuvant nivolumab administration for muscle-invasive bladder cancer","volume":"87","author":"Kamikawa","year":"2025","journal-title":"Nagoya J Med Sci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.2169\/internalmedicine.3028-23","article-title":"A rare case of overlapping durvalumab-induced myositis, takotsubo-like morphological changes caused by myocarditis, and myasthenia Gravis","volume":"63","author":"Saito","year":"2024","journal-title":"Intern Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.2169\/internalmedicine.1801-23","article-title":"Liver cancer with overlapping myasthenia Gravis, myocarditis, seronegative autoimmune autonomic ganglionopathy, and myositis symptoms induced by atezolizumab","volume":"63","author":"Shibuya","year":"2024","journal-title":"Intern Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/CAD.0000000000001727","article-title":"Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma","volume":"36","author":"Inan","year":"2025","journal-title":"Anticancer Drugs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"143","DOI":"10.25259\/JNRP_10_2022","article-title":"Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor","volume":"14","author":"\u00dcnl\u00fct\u00fcrk","year":"2023","journal-title":"J Neurosci Rural Pract"},{"key":"B58","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1080\/08923973.2023.2228480","article-title":"A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event","volume":"45","author":"Lin","year":"2023","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.hemonc.2020.04.006","article-title":"Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: a case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma","volume":"15","author":"Fuentes-Antr\u00e1s","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"950801","DOI":"10.3389\/fmed.2022.950801","article-title":"Myocarditis and myositis\/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: a case report and review of the literature","volume":"15","author":"Yin","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1053370","DOI":"10.3389\/fonc.2022.1053370","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: a case report and literature review","volume":"8","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"530","DOI":"10.14740\/jmc4008","article-title":"Literature review on neurological toxicities of programmed death protein 1 inhibitors","volume":"13","author":"Schwab","year":"2022","journal-title":"J Med Cases"},{"key":"B63","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/jcm12010130","article-title":"Myasthenia Gravis induced by immune checkpoint inhibitors: an emerging neurotoxicity in neuro-oncology practice: case series","volume":"12","author":"Marco","year":"2022","journal-title":"J Clin Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13256-022-03286-x","article-title":"Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report","volume":"16","author":"Saishu","year":"2022","journal-title":"J Med Case Rep"},{"key":"B65","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.3390\/jcm11195611","article-title":"Immune checkpoint inhibitor-induced myositis\/myocarditis with myasthenia Gravis-like misleading presentation: a case series in intensive care unit","volume":"11","author":"Deharo","year":"2022","journal-title":"J Clin Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1017\/cjn.2021.46","article-title":"Multiple immune-related adverse event overlap in two patients treated with pembrolizumab","volume":"49","author":"Jenkins","year":"2022","journal-title":"Can J Neurol Sci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"778185","DOI":"10.3389\/fonc.2021.778185","article-title":"Camrelizumab-related myocarditis and myositis with myasthenia Gravis: a case report and literature review","volume":"3","author":"Bai","year":"2022","journal-title":"Front Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"714460","DOI":"10.3389\/fcvm.2021.714460","article-title":"Case report: the neuromusclar triad of immune checkpoint inhibitors: a case report of myositis, myocarditis, and myasthenia Gravis overlap following toripalimab treatment","volume":"8","author":"Luo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"8512","DOI":"10.21037\/apm-20-2620","article-title":"Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review","volume":"10","author":"Chen","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"797009","DOI":"10.3389\/fcvm.2021.797009","article-title":"Sintilimab-induced myocarditis overlapping myositis in a patient with metastatic thymoma: a case report","volume":"23","author":"Yang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e18040","DOI":"10.7759\/cureus.18040","article-title":"Nivolumab-induced myasthenia Gravis concomitant with myocarditis, myositis, and hepatitis","volume":"13","author":"Bawek","year":"2021","journal-title":"Cureus"},{"key":"B72","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13256-021-02858-7","article-title":"Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report","volume":"15","author":"Cham","year":"2021","journal-title":"J Med Case Rep"},{"key":"B73","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13760-020-01282-w","article-title":"Myositis as a neuromuscular complication of immune checkpoint inhibitors","volume":"120","author":"Vermeulen","year":"2020","journal-title":"Acta Neurol Belg"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/imj.14946","article-title":"Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies","volume":"50","author":"Fazal","year":"2020","journal-title":"Intern Med J"},{"key":"B75","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40959-020-00076-6","article-title":"Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series","volume":"23","author":"Arora","year":"2020","journal-title":"Cardiooncology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"250","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma","volume":"8","author":"Xing","year":"2020","journal-title":"Ann Transl Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"5126717","DOI":"10.1155\/2020\/5126717","article-title":"The terrible triad of checkpoint inhibition: a case report of myasthenia Gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Reports Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2018.10.025","article-title":"Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody","volume":"106","author":"Shirai","year":"2019","journal-title":"Eur J Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ensci.2018.11.023","article-title":"Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life-threatening continuum of neuromuscular and cardiac toxicity","volume":"14","author":"Rota","year":"2018","journal-title":"eNeurologicalSci"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2539493","DOI":"10.1155\/2019\/2539493","article-title":"Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma","volume":"2019","author":"Fazel","year":"2019","journal-title":"Case Reports Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.lungcan.2019.06.015","article-title":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","volume":"135","author":"Konstantina","year":"2019","journal-title":"Lung Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/iju5.12128","article-title":"Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer","volume":"3","author":"Todo","year":"2019","journal-title":"IJU Case Rep"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1764567\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:51:01Z","timestamp":1773903061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1764567\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":83,"alternative-id":["10.3389\/fcvm.2026.1764567"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1764567","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"article-number":"1764567"}}